Please assess the completion status of the following clinical trial:

Trial Title: Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of cancer~* Scheduled to receive inpatient chemotherapy containing at least moderately emetogenic agents~  * May be given for adjuvant, neoadjuvant, curative, or palliative intent~ * May be given orally, IV, or by continuous infusion on ≥ 1 day~* Scheduled to receive 5-HT3 receptor antagonist antiemetic (e.g., ondansetron, granisetron, palonosetron, dolasetron mesylate, or dexamethasone with or without a benzodiazepine) on the day of chemotherapy~* Self-report of at least mild nausea (for which the patient feels needs rescuing) or moderate nausea (a score of ≥ 2 on a 4-point Likert scale) OR has had ≥ 1 episode of emesis since receiving chemotherapy~* No history of chronic nausea and/or vomiting (without chemotherapy), anticipatory nausea and/or vomiting, or emesis within 24 hours before chemotherapy~* No symptomatic brain metastases~PATIENT CHARACTERISTICS:~* Able to understand English~* Not pregnant or nursing~* Negative pregnancy test~* No clinical evidence of current or impending bowel obstruction (i.e., tumor pressing on the bowel)~* No allergy or intolerance to study drugs~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Prior chemotherapy allowed~* No aprepitant as prophylaxis or rescue treatment during the current course of chemotherapy (other than as a part of study therapy)~* Not scheduled to receive a dopamine antagonist after chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Fosaprepitant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).